Under the deal with Shimadzu, Proteome Systems will receive cash and the provision of Shimadzu’s latest mass spectrometer and protein separation technology.
This will position the Sydney-based company as a reference site for Shimadzu’s mass spectrometry technology and Shimadzu will have the benefit of Proteome Systems’s expertise in biomarker discovery methods for the development of new applications for its technology.
Proteome Systems’ CEO, Stephen Porges, said the move was integral to the overall corporate strategy of exiting its technology manufacturing operations to focus its resources on the significant successes of the core discovery and diagnostics business.
“This deal not only delivers on our previously stated strategy of reducing costs in our technology business, but also provides Proteome Systems with an ongoing strategic relationship with a global leader in the design and manufacture of analytical instruments, giving Proteome Systems direct access to the latest technology,” said Porges.
“Proteome Systems will become a reference site for Shimadzu, working on new mass spectrometry applications for discovery and validation of diagnostic markers and hosting visiting scientists from around the world.”
Diagnostics in development include Proteome Systems’s lead programme for a point of care test for active tuberculosis and a semen-based prostate cancer test.